Unleashing ferroptosis for cancer therapy with warfarin

Xiaoguang Liu; Li Zhuang; Boyi Gan

doi:10.1016/j.tem.2023.08.008

Unleashing ferroptosis for cancer therapy with warfarin

Trends Endocrinol Metab. 2023 Nov;34(11):683-684. doi: 10.1016/j.tem.2023.08.008. Epub 2023 Aug 28.

Authors

Xiaoguang Liu¹, Li Zhuang¹, Boyi Gan²

Affiliations

¹ Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA. Electronic address: bgan@mdanderson.org.

PMID: 37648560
DOI: 10.1016/j.tem.2023.08.008

Abstract

Ferroptosis holds promise for cancer therapy. A recent study by Yang et al. in Cell Metabolism reveals that VKORC1L1-mediated reduction of vitamin K inhibits ferroptosis and establishes a direct p53-VKORC1L1 link in its regulation. As warfarin can inhibit VKORC1L1, the study further underscores this drug's potential as a cancer therapy.

Keywords: VKORC1L1; ferroptosis; p53; vitamin K; warfarin.

MeSH terms

Ferroptosis*
Humans
Neoplasms* / drug therapy
Tumor Suppressor Protein p53
Vitamin K / metabolism
Vitamin K Epoxide Reductases / metabolism
Warfarin / pharmacology
Warfarin / therapeutic use

Substances

Warfarin
Vitamin K Epoxide Reductases
Vitamin K
Tumor Suppressor Protein p53

Abstract

MeSH terms

Substances

Grants and funding